BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $45

Moomoo NewsJan 14 10:32 ET · Ratings

Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $12

Moomoo NewsJan 14 10:32 ET · Ratings

Express News | Goldman Sachs Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $12

BenzingaJan 14 09:10 ET

A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $40 to $45

Moomoo NewsJan 14 08:00 ET · Ratings

Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), CareDx (CDNA) and Intellia Therapeutics (NTLA)

TipRanksJan 14 06:30 ET · Ratings

Oppenheimer Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $40

BenzingaJan 13 11:08 ET · Ratings